Previous 10 | Next 10 |
TELA Bio Inc. (TELA) is expected to report $-0.51 for Q3 2023
MALVERN, Pa., Oct. 26, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the pa...
MALVERN, Pa., Aug. 16, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc . (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patien...
2023-08-09 21:00:21 ET TELA Bio, Inc. (TELA) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Louisa Smith – Gilmartin Group Tony Koblish – President and Chief Executive Officer Roberto Cuca – Chief Operating Of...
2023-08-09 16:45:50 ET TELA Bio press release ( NASDAQ: TELA ): Q2 GAAP EPS of -$0.46 beats by $0.05 . Revenue of $14.5M (+39.4% Y/Y) beats by $0.1M . For further details see: TELA Bio GAAP EPS of -$0.46 beats by $0.05, revenue of $14.5M beats by $0.1M
MALVERN, Pa., Aug. 09, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own ana...
MALVERN, Pa., July 26, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the pa...
2023-06-21 20:00:00 ET Summary TELA Bio presents with reasonable financials, underlying market growth and business economics. However, the company's current lack of operating profitability is a factor to consider as well. Despite this, TELA should be closely monitored for pote...
MALVERN, Pa., June 15, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc . (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patien...
MALVERN, Pa., May 25, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own a...
News, Short Squeeze, Breakout and More Instantly...
MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the Canaccord Genuity 44 th Annual Growth Con...
MALVERN, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report second quarter 2024 financial results on Mon...
2024-06-27 06:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...